Market Overview

Novavax to Report Third Quarter 2012 Financial Results on November 2, 2012


ROCKVILLE, Md., Oct. 26, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2012 third-quarter financial results on Friday, November 2, 2012, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call hosted by Stanley C. Erck, President and Chief Executive Officer, and other members of senior management at 10:00a.m. Eastern time. The webcast and conference call will be available at under Investor Info/Events. The dial-in number for the conference call is 1 (877) 212-6076 (U.S. or Canada) or 1 (707) 287-9331 (International). Webcast and telephone replays of the conference call will be available shortly after the completion of the call. To access the replay by telephone, dial 1 (855) 859-2056 (Domestic) or 1 (404) 537-3406 (International) and use passcode 58585210.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant protein nanoparticle vaccine technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website,

CONTACT: Frederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000
View Comments and Join the Discussion!